Personalis Expands Partnership with Tempus to Enhance MRD Testing for Cancer Management

Strengthening Cancer Management Through Innovative Partnerships

Personalis, Inc. and Tempus AI, Inc. have announced a significant expansion of their commercial partnership to enhance the availability of ultra-sensitive minimal residual disease (MRD) testing. Originally established in November 2023, this collaboration positions Tempus as the exclusive commercial diagnostic partner for Personalis' NeXT Personal® Dx product. The focus of this partnership is to improve patient access to MRD testing for breast and lung cancers, as well as for monitoring immunotherapy across a range of solid tumors. This strategic move reflects a growing recognition of the importance of MRD testing in oncology, particularly for early detection and personalized treatment strategies.

The recent development is particularly noteworthy as it extends the partnership beyond the diagnostic market into the biopharma sector. Tempus will now be able to offer NeXT Personal to pharmaceutical and biotech companies, allowing them to bundle this advanced MRD testing with other Tempus services in their clinical studies. This transition aims to facilitate the integration of cutting-edge genomic profiling into drug development processes, ultimately enhancing the precision of cancer therapies. Chris Hall, CEO of Personalis, expresses optimism that this expansion will accelerate the market penetration of their MRD platform and broaden their engagement with the biopharma industry, which is increasingly focused on personalized medicine.

Personalis is committed to transforming cancer management through its innovative solutions, which combine tumor and normal profiling with proprietary algorithms. These advanced assays not only aid in the early detection of MRD and cancer recurrence but also support the selection of targeted therapies tailored to individual patients. As the companies prepare to present their collaborative efforts at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, they reaffirm their dedication to advancing cancer management through innovation and collaboration, despite the inherent risks and uncertainties present in the healthcare market.

In addition to the partnership expansion, both Personalis and Tempus emphasize their focus on improving patient outcomes through innovative technology and comprehensive genomic insights. By leveraging their combined expertise, the companies aim to set new standards in cancer diagnostics and treatment, ultimately enhancing the quality of care for patients battling various forms of cancer. For further details on their offerings, interested parties can visit Personalis' website at www.personalis.com.